Diabetes, obesity & metabolism, 2018-01, Vol.20 (1), p.94-102
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
- Ist Teil von
- Diabetes, obesity & metabolism, 2018-01, Vol.20 (1), p.94-102
- Ort / Verlag
- Oxford, UK: Blackwell Publishing Ltd
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Aim To test the hypothesis that an improving body composition in insulin‐resistant individuals could enhance insulin sensitivity. Methods A total of 16 people with a mean body mass index of 29.3 kg/m2 and insulin resistance, received a single dose of bimagrumab or placebo and were assessed at week 10 for insulin sensitivity, using a hyperinsulinaemic‐euglycaemic clamp and an intravenous glucose tolerance test (IVGTT), and for body composition using dual energy X‐ray absorptiometry and positron‐emission tomography. Results Bimagrumab increased lean mass by 2.7% (P < .05) and reduced fat mass by 7.9% (P = .011) at week 10 compared with placebo, and had a neutral effect on body weight. Bimagrumab reduced glycated haemoglobin by 0.21% at week 18 (P < .001) and improved insulin sensitivity by ~20% (according to the clamp) to ~40% (according to the IVGTT). Conclusion Taking the observed changes together, and given that these occurred without accompanying dietary intervention and without any prescribed regular physical exercise, bimagrumab may offer a novel approach for the treatment of the metabolic complications of obesity.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1462-8902eISSN: 1463-1326DOI: 10.1111/dom.13042Titel-ID: cdi_proquest_miscellaneous_1913399547
- Format
- –
- Schlagworte
- Absorptiometry, Photon, activin receptor II, Adipose Tissue, Brown - diagnostic imaging, Adipose Tissue, Brown - drug effects, Adipose Tissue, Brown - metabolism, Adiposity - drug effects, Anti-Obesity Agents - administration & dosage, Anti-Obesity Agents - adverse effects, Anti-Obesity Agents - pharmacokinetics, Anti-Obesity Agents - therapeutic use, Antibodies, Blocking - administration & dosage, Antibodies, Blocking - adverse effects, Antibodies, Blocking - therapeutic use, Antibodies, Monoclonal - administration & dosage, Antibodies, Monoclonal - adverse effects, Antibodies, Monoclonal - pharmacokinetics, Antibodies, Monoclonal - therapeutic use, bimagrumab, Body composition, Body fat, Body Mass Index, Body weight, Double-Blind Method, Dual energy X-ray absorptiometry, Female, Follow-Up Studies, Glucose, Glucose Clamp Technique, Glucose Intolerance - blood, Glucose Intolerance - complications, Glucose Intolerance - drug therapy, Glucose Intolerance - metabolism, Glucose tolerance, Glucose Tolerance Test, Glycated Hemoglobin A - analysis, HbA1c, Hemoglobin, Humans, Hypoglycemic Agents - administration & dosage, Hypoglycemic Agents - adverse effects, Hypoglycemic Agents - pharmacokinetics, Hypoglycemic Agents - therapeutic use, Infusions, Intravenous, Insulin, Insulin Resistance, Intravenous administration, Male, Obesity, Obesity - complications, Obesity - diagnostic imaging, Obesity - drug therapy, Obesity - metabolism, Pilot Projects, Positron emission tomography, Positron Emission Tomography Computed Tomography, Thermogenesis - drug effects